Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. More Details
High growth potential with imperfect balance sheet.
Share Price & News
How has Agile Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AGRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: AGRX's weekly volatility (9%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: AGRX underperformed the US Pharmaceuticals industry which returned 17.5% over the past year.
Return vs Market: AGRX underperformed the US Market which returned 35.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Agile Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 months ago | Simply Wall StHow Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Did Insiders Buy, In The Last Year?
6 months ago | Simply Wall StHow Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Do Institutions Own?
Is Agile Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AGRX's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AGRX's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AGRX is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: AGRX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AGRX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AGRX is overvalued based on its PB Ratio (4.6x) compared to the US Pharmaceuticals industry average (2.9x).
How is Agile Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AGRX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: AGRX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AGRX's is expected to become profitable in the next 3 years.
Revenue vs Market: AGRX's revenue (55.2% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: AGRX's revenue (55.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AGRX's Return on Equity is forecast to be high in 3 years time
How has Agile Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AGRX is currently unprofitable.
Growing Profit Margin: AGRX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AGRX is unprofitable, and losses have increased over the past 5 years at a rate of 14.5% per year.
Accelerating Growth: Unable to compare AGRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AGRX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.9%).
Return on Equity
High ROE: AGRX has a negative Return on Equity (-275.95%), as it is currently unprofitable.
How is Agile Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: AGRX's short term assets ($36.9M) exceed its short term liabilities ($11.6M).
Long Term Liabilities: AGRX's short term assets ($36.9M) exceed its long term liabilities ($16.0M).
Debt to Equity History and Analysis
Debt Level: AGRX's debt to equity ratio (65.2%) is considered high.
Reducing Debt: AGRX's debt to equity ratio has increased from 29.1% to 65.2% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AGRX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: AGRX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 9.4% each year
What is Agile Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AGRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AGRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AGRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AGRX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AGRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Al Altomari (62 yo)
Mr. Alfred F. Altomari, also known as Al, has been an Independent Chairman of the Board of Baudax Bio Inc. since November 2019. He has been the Chief Executive Officer at Agile Therapeutics, Inc. since Oct...
CEO Compensation Analysis
Compensation vs Market: Al's total compensation ($USD2.40M) is above average for companies of similar size in the US market ($USD551.32K).
Compensation vs Earnings: Al's compensation has increased whilst the company is unprofitable.
Experienced Management: AGRX's management team is considered experienced (2.9 years average tenure).
Experienced Board: AGRX's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AGRX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.6%.
Agile Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Agile Therapeutics, Inc.
- Ticker: AGRX
- Exchange: NasdaqCM
- Founded: 1997
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$113.460m
- Shares outstanding: 93.00m
- Website: https://www.agiletherapeutics.com
Number of Employees
- Agile Therapeutics, Inc.
- 101 Poor Farm Road
- New Jersey
- United States
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known a...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/08/03 00:36|
|End of Day Share Price||2021/08/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.